Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Biotechnology
Shares of US clinical-stage biotech Tenaya Therapeutics closed up more than 40% at $0.82 yesterday following its announcement of a potentially lucrative collaboration. 6 March 2026
Related News
Insights
Company Spotlight
A Nasdaq-listed biopharmaceutical company developing small-molecule medicines for cardiovascular, metabolic and neurological diseases. Lexicon Pharmaceuticals focuses on therapies discovered through genetic and molecular research designed to address serious chronic conditions.
Latest News & Features of interest to Alnylam Pharmaceuticals
Pharmaceutical
US drugmaker AbbVie has announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. 24 February 2026
Biotechnology
US biotech Moderna has won a fresh review from the US regulator for its seasonal influenza shot mRNA-1010, with a PDUFA decision due August 5, 2026, after an earlier refusal-to-file letter stalled the program. 24 February 2026
Pharmaceutical
UK biotech N4 Pharma has appointed David Solomon as chief executive and unveiled plans to rename itself Thalia Therapeutics, marking a decisive shift into proprietary RNA medicines focused initially on cardiovascular disease. 24 February 2026
Pharmaceutical
US biotech Gossamer Bio saw its shares collapse 81% after its Phase III PROSERA study of seralutinib in pulmonary arterial hypertension (PAH) missed a prespecified statistical bar, denting hopes of challenging Merck & Co’s (NYSE: MRK)Winrevair (sotatercept). 24 February 2026
Biosimilars
Switzerland’s Sandoz has reported that the European Commission has granted marketing authorization for Ranluspec, a biosimilar ophthalmology drug referencing Lucentis (ranibizumab). 23 February 2026
Pharmaceutical
Taiwanese biotech Formosa Pharmaceuticals has granted Arrotex Pharmaceuticals exclusive rights to commercialize APP13007 (clobetasol propionate) in Australia and New Zealand for post-surgical eye inflammation and pain. 23 February 2026
Pharmaceutical
Regulatory news last week included US drug developer Cytokinetics gaining European Commission approval for its cardiomyopathy drug Myqorzo. Swedish biotech Hansa Biopharma said the US Food and Drug Administration (FDA) has accepted its biologics license application (BLA) for imlifidase for review and the FDA approved UK pharma major AstraZeneca’s Calquence plus venetoclax for lymphocytic leukemia. Also of note, US major Eli Lilly entered a licensing deal with Australia’s CSL Limited for the commercialize clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAb) for the prevention of cardiovascular events in patients with end-stage kidney disease (ESKD). 22 February 2026
Biotechnology
US drugmaker Eli Lilly has announced positive top-line results from the landmark TOGETHER-PsO open-label Phase IIIb trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. 19 February 2026
Pharmaceutical
US pharma giant Merck & Co and hospital system Mayo Clinic have announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data, to support drug discovery and development. 19 February 2026
Pharmaceutical
Ocular Therapeutix has announced positive top-line results from the SOL-1 Phase III superiority trial of Axpaxli - also known as OTX-TKI - its investigational product candidate, for the treatment of wet age-related macular degeneration (AMD). 18 February 2026
Latest In Brief for Alnylam Pharmaceuticals
Pharmaceutical
Israel-based generics giant Teva Pharmaceutical Industries and France’s Medincell announced that the US Food and Drug Administration has accepted the New Drug Application for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. 21 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze